In areas where malaria is endemic, the risk of malaria starts in the early neonatal period, with congenital infections recognized as an important cause of morbidity \[[@bib1]--[@bib4]\]. The asymptomatic nature of infection in the early stages is likely to result in its true incidence being underestimated \[[@bib5], [@bib6]\].

In highly endemic areas of Africa, up to a third of infants acquire malaria in utero \[[@bib7]--[@bib10]\]. Vertical transmission is less well described in the Asia Pacific region, descriptions of its epidemiology often relying on case series/reports or maternal or placental malaria studies that are generally of small sample size \[[@bib11]--[@bib15]\]. In the present study we sought to define the risks of vertical malaria transmission along with its treatment and prevention in \> 4000 neonates born in the local hospital in Timika, Papua-Indonesia, an area with highly prevalent drug-resistant *Plasmodiumfalciparum* and *P. vivax* \[[@bib16]\].

METHODS
=======

Study Site
----------

The study was conducted in southern Papua, Indonesia. This area is largely forested, with both coastal and mountainous areas. Malaria transmission is restricted to the lowland area, where it is associated with 3 mosquito vectors: *Anopheles koliensis*, *A. farauti*, and *A. punctulatus*. Until November 2008, Rumah Sakit Mitra Masyarakat (RSMM) hospital, Timika, was the only hospital in this district servicing an area of 21 522 km^2^, with a population of ∼200 000 people. The annual incidence of malaria in the region is 876 per 1000 person-years, divided 60:40 between *P. falciparum* and *P. vivax* infections \[[@bib17]\]. In this region, high levels of antimalarial drug resistance are present in both species, the risk of failure within 28 days reaching 65% after chloroquine monotherapy for *P. vivax* and 48% after chloroquine plus sulfadoxine-pyrimethamine for *P. falciparum* \[[@bib16]\].

Study Population
----------------

The infant mortality rate in southern Papua is estimated as 68 per 1000 live births \[[@bib18]\], with malaria being the most common cause of morbidity in the first year of life, followed by diarrhea and lower respiratory tract infections \[[@bib19]\]. Malaria accounts for 30% and 14% of infant hospital admissions and outpatient visits, respectively \[[@bib4]\]. Due to economic migration, the ethnic origin of the local population is diverse, with highland Papuans, lowland Papuans, and non-Papuans all resident in the region. Hospital policy dictates that all patients presenting with a febrile illness, irrespective of other symptoms, should have blood film examination for malaria.

Data Collection
---------------

From April 2004 hospital protocol dictated that all infants born at RSMM were to be screened for malaria within 3 days of birth. After obtaining parental/legal guardian consent, the malaria smear results were documented, and a trained research nurse or research physician performed systematic physical examination of the baby to assess clinical signs, gestational age (using New Ballard Score) \[[@bib20]\], and the presence of external congenital malformations. Babies with a birth weight \< 2500 g were defined as having a low birth weight (LBW), and those with gestational age of \< 37 weeks, as being premature. External congenital malformation was diagnosed based on the *International Classification of Diseases* 10 \[[@bib21]\]. Maternal clinical and laboratory data at delivery were also collected as described elsewhere \[[@bib22]\].

If the newborn had malaria, a more detailed questionnaire on clinical and laboratory data was completed. In order to determine late congenital manifestations, all infants younger than 3 months old admitted with malaria to the pediatric wards were identified and invited to be part of the study. In the latter case maternal data at delivery were retrieved from hospital records if the infant was born at RSMM. A research nurse documented history of illness (including fever, restlessness, poor feeding, cough, and breathlessness) and weight of the infants. The infant was examined, and pulse, respiratory rate, and the presence of splenomegaly and hepatomegaly were recorded. Temperature was recorded per axilla, with fever defined as a temperature \>37.5°C. Severe anemia was defined as having hemoglobin concentration \<5 g/dL \[[@bib23]\].

Malaria was diagnosed by microscopy of Giemsa-stained blood films. Slides were read by an expert microscopist and considered negative after review of 200 high-power fields. Parasite counts were determined from the number of parasites per 200 white blood cells (WBC) on Giemsa-stained thick films. Peripheral parasitemia was calculated from the recorded white cell count. A thin smear was also examined to confirm parasite species and used for quantification if parasitemia was \> 200 per 200 WBC.

As clinically indicated, venous blood samples (1--5 mL) were drawn from infants admitted with malaria to the pediatric wards for complete blood counts and hemoglobin concentration (using electronic counter---Coulter JT). Venous sampling was not routinely conducted in neonates (age \< 28 days) with peripheral malaria parasitemia unless requested by the attending clinician.

All infants with peripheral parasitemia received standard antimalarial therapy and supportive care as per hospital protocol. Before March 2006, young infants and pregnant women with uncomplicated malaria of any species were treated with quinine for 7 days (intravenous quinine was used for severe malaria). After March 2006, local protocols were changed to recommend dihydroartemisinin-piperaquine (DHP) for uncomplicated malaria in infants weighing \> 5 kg and in pregnant women in the second and third trimesters of pregnancy. Neonates weighing \< 5 kg were treated with oral quinine, and women in the first trimester, with quinine and clindamycin. Neonates and pregnant women with severe malaria were treated with intravenous artesunate \[[@bib24]\].

Statistical Analysis
--------------------

Data from the questionnaire and the laboratory were entered into EpiData 3.02 software (EpiData Association). Data were analyzed using SPSS vs 17.0 for Windows software (SPSS Inc). Normally distributed data were compared by Student *t* test. Data not conforming to a normal distribution were compared by the Mann--Whitney *U* test. Categorical data were compared by calculating the χ^2^ with Yates's correction or by Fisher's exact test and the odds ratio (OR) with 95% confidence intervals (CIs). Multiple logistic regression was used to analyze independent risk factors for congenital malaria by entering all significant risk factors in univariate analysis.

Ethical Approval
----------------

Ethical approval for this study was obtained from the ethics committees of the National Institute of Health Research and Development, Ministry of Health, Indonesia; and the Human Research Ethics Committee of the Menzies School of Health Research and Department of Health, Darwin, Australia.

RESULTS
=======

Congenital Malaria
------------------

Between April 2004 and January 2010, 4884 (85%) of 5728 babies born at RSMM were screened for malaria ([Figure 1](#fig1){ref-type="fig"}). In total, 38 (0.8%) neonates were diagnosed with congenital infection within the first 3 days of life. *P. falciparum* accounted for 76.3% (29) of infections; *P. vivax*, for 15.8% (6); *P. ovale*, for 2.6% (1); and mixed species, for 5.3% (2). There was 1 pair of twins with congenital malaria, both of whom had *P. falciparum*. The median parasite density of the newborns was 100 μL^−1^ (range, 50--26 700 μL^−1^). All newborns were asymptomatic, with the exception of 1 baby with high parasitemia and severe malaria manifest as neonatal sepsis syndrome, as reported previously \[[@bib25]\]. The median parasitemia was similar between infants infected with *P. falciparum* (100 μL^−1^; range, 50--26 688 μL^−1^) and *P. vivax* (125 μL^−1^; range, 50--300 μL^−1^; *P* = 1.0).
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Newborns with congenital malaria had a lower birth weight (mean, 2764; 95% CI, 2553--2975 g; with 32.4% \[12/37\] having LBW), compared with newborns without malaria (mean, 3031; 95% CI, 2997--3028 g; 13.3% (642/4838) with LBW; *P* = .02), the OR for LBW being 3.1 (95% CI, 1.6--6.3; *P* = .002). The effect of congenital malaria on LBW remained after controlling for other known risk factors in this population (maternal age, parity, maternal malaria, and severe anemia; adjusted odds ratio \[AOR\], 2.7; 95% CI, 1.1--6.5; *P* = .03).

Antimalarials were given to all parasitemic newborns, with 32 receiving quinine (oral ± intravenous); 2, intravenous artesunate followed with DHP; and 4, oral DHP alone. All malaria smears were negative at time of discharge from hospital.

Maternal Parasitemia and Vertical Transmission
----------------------------------------------

Data on the blood film examination of the mothers were available in 4878 women, the prevalence of maternal malaria being 19% (928; [Table 1)](#tbl1){ref-type="table"}. Of the 37 recorded cases of early vertical transmission, 9 (24%) were born from aparasitemic mothers. In the remaining 28 women with malaria at delivery, 5 had neonates with different parasite species, giving rise to discordance in 18% of cases ([Table 1](#tbl1){ref-type="table"}).

###### 

Vertical Malaria Transmission Profile

                              Parasitemia at birth[a](#tblfn1){ref-type="table-fn"}                                                 
  --------------------------- ------------------------------------------------------- ----------- ---------- ---------- ----------- ----------
  Negative (n = 3948)         3939 (99.8)                                             8 (0.2)     1 (0.02)   0          0           9 (0.2)
  *P. falciparum* (n = 501)   488 (97.2)                                              12 (2.4)    1 (0.2)    0          0           13 (2.5)
  *P. vivax* (n = 321)        314 (97.8)                                              3 (0.9)     4 (1.2)    0          0           7 (2.2)
  *P. ovale* (n = 3)          2 (66.7)                                                0 (0)       0 (0)      1 (33.3)   0           1 (33.3)
  *P. malariae* (n = 50)      49 (98)                                                 1 (2)       0 (0)      0          0           1 (2)
  Mixed infection (n = 53)    47 (88.7)                                               4 (7.5)/3   0 (0)      0          2 (3.8)/2   6 (11)

All data are no. of cases (%).

Where deliveries included multiple births, vertical transmission was reported if at least 1 of the babies was found to be parasitemic.

Maternal Risk Factors
---------------------

Maternal risk factors for vertical transmission are shown in [Table 2](#tbl2){ref-type="table"}. The risk of vertical transmission was 3% in women with peripheral parasitemia at delivery compared with 0.2% in those aparasitemic (OR, 13.6; 95% CI, 6.4--28.9; *P* \< .001), with the population attributable risk of congenital infection being 70%. The risk of transmission did not vary with magnitude of maternal peripheral parasitemia even after controlling for the species of infection ([Table 3](#tbl3){ref-type="table"}). Afebrile mothers with malaria had a risk of transmitting the parasites vertically (2.5%, 16/642) comparable to symptomatic parasitemic mothers (4.2%, 12/284; *P* = .21). Regardless of parasitemia status at delivery, women with possible history of malaria infection during pregnancy had a 4.1-fold (95% CI, 2.1--7.9) greater risk of vertical transmission to the fetus compared with mothers without any history of malaria infections (*P* \< .001). In the multivariate models, maternal malaria at delivery, history of malaria during pregnancy, and maternal age ≤ 16 years old remained as independent risk factors for vertical transmission ([Table 2](#tbl2){ref-type="table"}). Together these factors explained 89% of all congenital infections.

###### 

Maternal Risk Factors for Vertical Malaria Transmission

                                             Prevalence n/valid cases (%)   Prevalence of cases exposed to factor n/valid cases (%)   Univariate analysis   PAR      Multivariate analysis   PAR                        
  ------------------------------------------ ------------------------------ --------------------------------------------------------- --------------------- -------- ----------------------- ----------------- -------- ------
  Maternal peripheral parasitemia at birth   928/4878 (19)                  28/37 (75)                                                13.6 (6.4--28.9)      \<.001   70%                     9.5 (4.2--21.5)   \<.001   68%
      No.                                    3950/4878 (81)                 9/37 (24)                                                 ...                   ...      ...                     1                 1        ...
      *P. falciparum* malaria                501/4878 (10)                  13/37 (35)                                                11.6 (4.9--27.4)      \<.001   32%                     7.6 (2.9--19.4)   \<.001   30%
      *P. vivax* malaria                     321/4878 (6.6)                 7/37 (18.9)                                               9.7 (3.6--26.4)       \<.001   17%                     6.9 (2.4--19.3)   \<.001   16%
  Maternal fever                             365/4877 (7.5)                 13/37 (35)                                                6.9 (3.5--13.7)       \<.001   30%                     1.6 (.8--3.4)     .207     13%
  Maternal history of febrile illness        925/4881 (19)                  18/37 (48.6)                                              4 (2.1--7.9)          \<.001   36%                     2.2 (1.1--4.4)    .022     26%
  Young mother (\< 16 years old)             118/4879 (2.4)                 4/37 (10.8)                                               5 (1.7--14.4)         .012     8.6%                    4.1 (1.4--12.1)   .011     8.2%
  Primipara                                  1527/4878 (31)                 12/37 (32.4)                                              1.05 (.5--2.1)        .860     ...                     ...               ...      ...
  Severe anemia                              333/4740 (6.8)                 3/36 (8.3)                                                1.2 (.4--3.9)         .74      ...                     ...               ...      ...
  Preterm delivery                           748/4865 (15.3)                8/37 (21.6)                                               1.5 (.7--3.3)         .260     ...                     ...                        ...

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio; PAR, population attributable risk, calculated as \[(proportion of cases exposed to risk factor) × (OR -- 1)\]/OR.

###### 

Maternal Parasitemia at Delivery and Vertical Malaria Transmission

  Maternal parasitemia (geometric mean/μL)   Vertical malaria transmission           *P* value           
  ------------------------------------------ --------------------------------------- ------------------- ------
  *P. falciparum*                            403 (81--1998)                          1480 (1211--1998)   .098
  *P. vivax*                                 2186[a](#tblfn2){ref-type="table-fn"}   665 (200--1998)     ...

One case only.

Malaria Treatment in Pregnancy
------------------------------

In total 905 pregnant women described a prior febrile episode during their pregnancy and were treated with antimalarial medication, with vertical transmission of infection observed in 18 (2%) births. DHP was introduced as first-line treatment of uncomplicated malaria in the second and third trimesters of pregnancy since March 2006. Babies born of mothers with a history of DHP treatment during pregnancy had a significantly lower risk of malaria (0.2%, 1/471) compared with those with prior exposure to chloroquine/quinine treatment (4.9%, 17/348; OR, 0.04; 95% CI, .005--.3; *P* \< .001). The number of congenital malaria cases declined significantly following the change in malaria treatment policy, from 3.2% (29/907) before policy change to 0.2% (9/3912) after (OR, 0.07; 95% CI, .03--.15; *P* \< .001). There has been no reported congenital malaria case since October 2008 ([Figure 2](#fig2){ref-type="fig"}). After controlling for other confounding factors, malaria treatment policy change remained as a protective factor for congenital malaria (AOR, 0.18; 95% CI, .032--.89; *P* = .036).
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Possible Late Manifestation of Congenital Infection
---------------------------------------------------

Of 4878 hospital deliveries, 74 infants from 72 mothers (66 singletons, 4 half twins, and 2 sets of twin) were readmitted to the hospital in the first 3 months of life with symptomatic malaria. All of these infants had been screened at birth with negative blood films. On readmission, *P. falciparum* accounted for 20% (15), *P. vivax* for 76% (56), and mixed species for 4% (3) of the infections. One infant (92 days old) with mixed *P. falciparum* and *P. vivax* malaria had severe anemia and died within 24 hours of hospitalization. All other children were discharged from hospital after a median of 3 days' (interquartile range, 1--2) inpatient stay.

The major maternal factors associated with admission of an infant to hospital with malaria in the first 3 months of life were maternal malaria at delivery (OR, 3.3; 95% CI, 2.1--5.3; *P* \< .001) and a history of malaria during pregnancy (OR, 1.8; 95% CI, 1.1--3; *P* = .024). LBW infants and twins had a 2.3-fold (95% CI, 1.3--3.8; *P* = .005) and 3.5-fold (95% CI, 1.6--7.9; *P* = .01) higher risk of malaria in early life compared with those with normal birth weight and singletons, respectively.

DISCUSSION
==========

This large surveillance study defines the epidemiology of congenital malaria and its outcome after treatment in Papua, Indonesia, an area co-endemic for both vivax and falciparum malaria. Congenital malaria was observed in 0.8% of live births, with the risk of vertical transmission rising almost 10-fold in women with peripheral parasitemia at delivery. This incidence was significantly lower than that reported from areas of high malaria transmission in Africa, which, with some exceptions \[[@bib26]\], has generally ranged from 5% to 33% \[[@bib8]--[@bib10]\] and even higher (19%--50%) in women with peripheral parasitemia \[[@bib7], [@bib9], [@bib10]\]. Contrary to previous hypotheses, these findings suggest that vertical transmission may be determined by other factors than just the level of malaria exposure and associated maternal immunity \[[@bib27]\].

In almost 20% of cases the parasite species in the baby was discordant with the peripheral parasitemia of the mother. Vertical transmission of malaria occurring antenatally is well described in both African and Southeast Asian settings \[[@bib8], [@bib9], [@bib11], [@bib14], [@bib25], [@bib28], [@bib29]\], and this may explain some of the materno-neonatal discordance in parasite species. In addition, the vertical transmission of infection may reflect the species of placental infection, in which case the peripheral parasitemia may be an incidental finding. However, because we did not routinely examine placental tissue, we were unable to investigate this further.

Most reports of congenital malaria originate from sub-Saharan Africa, where the majority of infections are due to *P. falciparum*. The epidemiology of congenital infection in Asia and South America is less well described. In these regions, where *P. falciparum* and *P. vivax* are co-endemic, vertical transmission can occur with either species \[[@bib11], [@bib14]\]. In the present study we routinely screened all babies within 3 days of birth and were thus able to reliably exclude infections acquired early in the postnatal period. *P.vivax* congenital infection (alone or mixed) occurred in 1.6 per 1000 live births and accounted for 22% of all congenital infections. Although the median *P. falciparum* parasitemia observed in newborns in Papua was higher (100 μL^−1^; range, 50--26 688 μL^−1^) than that reported in Africa (48 μL^−1^; range, 8--200 μL^−1^) \[[@bib9]\], infections in Papua were almost all asymptomatic, compared with a third of infections being symptomatic in an African study undertaking active screening. These findings could not be explained by early detection since in both studies active screening was conducted at birth.

Fetal exposure to malarial parasites in utero has been proposed to modify the immune response of newborns, increasing their susceptibility to symptomatic malaria infections at birth and later in life \[[@bib30]--[@bib32]\]. In Africa, where peripheral parasitemia and placental malaria are highly prevalent, this increased susceptibility is associated with a greater risk of neonatal parasitemia and clinical malaria \[[@bib27], [@bib33]\]. In such settings neonatal screening is often reserved for symptomatic infants. However, in lower-transmission areas the consequence of leaving asymptomatic congenital malaria untreated may be significantly associated with greater malaria morbidity in early life \[[@bib4]\]. As such, early detection by active screening of all babies is warranted where resources permit.

African infants with congenital malaria are at greater risk of LBW than aparasitemic infants \[[@bib7], [@bib10]\], and a similar observation was apparent in our Papuan study. Premature delivery associated with maternal malaria could not explain this increased risk, suggesting that other factors such as placental infection and insufficiency may play a crucial role in reducing fetal growth \[[@bib34]\].

Our study highlights the importance of ensuring the effective treatment of maternal malaria. DHP has excellent efficacy against both multidrug-resistant *P. falciparum* and *P. vivax*. In March 2006 local guidelines for the treatment of maternal malaria in the second and third trimesters of pregnancy were changed from chloroquine plus sulfadoxine-pyrimethamine or quinine to DHP. Over the ensuing 3 years this policy has been associated with a large reduction in the incidence of congenital malaria. Indeed we have not witnessed a case of congenital malaria since October 2008, despite screening almost 1416 babies for malaria. Chloroquine and sulfadoxine-pyrimethamine have been the main treatment options for maternal malaria in most parts of Africa \[[@bib9], [@bib35], [@bib36]\], but these policies are threatened by high rates of aminoquinoline and antifolate drug resistance. This may in part explain the high rates of congenital malaria reported from a number of sites in the continent \[[@bib7], [@bib9], [@bib10]\] and further emphasizes the need for exploring more effective and reliable treatment strategies in pregnancy. In Kenya, congenital malaria has fallen in recent years in parallel with the fall in general community malaria burden, suggesting that malaria control interventions targeting the whole community may also contribute to reductions in congenital malaria \[[@bib26]\].

There are a number of limitations to our study. We were reliant on microscopy of peripheral blood film for diagnosing malaria, and this is likely to have underestimated the real burden of congenital malaria by missing low-parasitemia infections and misdiagnosis of the species of infection \[[@bib37]\]. The use of polymerase chain reaction diagnostics in previous reports may have detected a higher proportion of infections \[[@bib29]\]. In addition, the lack of cord blood parasitemia and placental malaria data in our study will have also underestimated the true burden of congenital malaria \[[@bib9], [@bib29]\]. The risks to the baby documented in this article are therefore conservative estimates.

Currently, there are no consensus international guidelines for the case management of congenital malaria. In Africa asymptomatic congenital malaria is often left untreated if the parasites are cleared within 3 days \[[@bib10]\]. Chloroquine and sulfadoxine-pyrimethamine have been used previously for treating congenital falciparum malaria \[[@bib7], [@bib38]\], but with increasing antimalarial drug resistance, these treatments can no longer be advocated \[[@bib16], [@bib39]\].

At our study site all infants with positive blood films were treated with antimalarial drugs irrespective of symptomatology; however, treatment options in this region are limited \[[@bib4]\]. Due to the high prevalence of multidrug resistance in both *P. falciparum* and *P. vivax* \[[@bib16]\], local guidelines recommend that infants \<5 kg in weight with malaria should be treated with either a 7-day course of oral quinine or, if unable to tolerate oral medication, intravenous artesunate followed with DHP. In the current report all infants responded well to treatment, although they were not systematically followed up after discharge from hospital. The reality is that compliance with unsupervised 7-day courses of oral quinine is rare, and as a result, late recurrence rates are high \[[@bib16]\]. Therefore, evidence for the safety and efficacy of reliable short-course treatment regimens is urgently required for malaria in neonates and young infants.

In conclusion, our study provides insights into the epidemiology of congenital malaria in endemic areas outside Africa. The introduction of a highly effective artemisinin combination therapy for malaria treatment in the second and third trimesters of pregnancy was associated with a marked decrease in the risk of congenital malaria. Routine screening of newborns for asymptomatic parasitemia followed by prompt, effective antimalarial treatment could reduce malaria burden in early life even further.
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